Stig Hansen has been President and CEO of Kimia Therapeutics since January 2023. He co-founded Carmot Therapeutics in 2008, where he led the advancement of Chemotype Evolution and developed a pipeline that includes three clinical-stage incretin modulators for metabolic diseases. Prior to Carmot, Hansen was Director of Biology at Sunesis Pharmaceuticals, where he invented Chemotype Evolution. He holds an MS in biochemistry and a PhD in molecular and cell biology from the University of Copenhagen and was a Novartis Fellow studying mammalian brain development at UC Berkeley.